The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Open accessAbstract
Objective: To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, Brazil during widespread circulation of the gamma variant. Design: Test negative case-control study. Setting: Community testing for covid-19 in São Paulo state, Brazil. Participants: 43 774 adults aged ≥70 years who were residents of São Paulo state and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 29 April 2021. 26 433 cases with symptomatic covid-19 and 17 622 test negative controls with covid-19 symptoms were formed into 13 283 matched sets, one case with to up to five controls, according to age, sex, self-reported race, municipality of residence, previous covid-19 status, and date of RT-PCR test (±3 days). Intervention: Vaccination with a two dose regimen of CoronaVac. Main outcome measures: RT-PCR confirmed symptomatic covid-19 and associated hospital admissions and deaths. Results: Adjusted vaccine effectiveness against symptomatic covid-19 was 24.7% (95% confidence interval 14.7% to 33.4%) at 0-13 days and 46.8% (38.7% to 53.8%) at ≥14 days after the second dose. Adjusted vaccine effectiveness against hospital admissions was 55.5% (46.5% to 62.9%) and against deaths was 61.2% (48.9% to 70.5%) at ≥14 days after the second dose. Vaccine effectiveness ≥14 days after the second dose was highest for the youngest age group (70-74 years)—59.0% (43.7% to 70.2%) against symptomatic disease, 77.6% (62.5% to 86.7%) against hospital admissions, and 83.9% (59.2% to 93.7%) against deaths—and declined with increasing age. Conclusions: Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant. Vaccine protection was, however, low until completion of the two dose regimen, and vaccine effectiveness was observe to decline with increasing age among this elderly population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Age-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01429-x · Cited by 898
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107715 · Cited by 866
Analysis of matched case-control studies
Pearce, N. (2016) · BMJ · doi:10.1136/bmj.i969 · Cited by 771
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., The CITIID-NIHR BioResource COVID-19 Collaboration, Principal Investigators, et al. (2021) · Nature · doi:10.1038/s41586-021-03739-1 · Cited by 751
Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30987-7 · Cited by 541
Ranzani, O. T., Bastos, L. S. L., Gelli, J. G. M., Marchesi, J. F., Baião, F., Hamacher, S., & Bozza, F. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30560-9 · Cited by 513
Self-citationBajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
Naveca, F. G., Nascimento, V., de Souza, V. C., Corado, A. D. L., Nascimento, F., Silva, G., Costa, Á., Duarte, D., Pessoa, K., Mejía, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01378-7 · Cited by 462
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
de Souza, W. M., Buss, L. F., Candido, D. D. S., Carrera, J.-P., Li, S., Zarebski, A. E., Pereira, R. H. M., Prete, C. A., de Souza-Santos, A. A., Parag, K. V., et al. (2020) · Nature Human Behaviour · doi:10.1038/s41562-020-0928-4 · Cited by 422
Self-citationSARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Chernet, R. L., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00068-9 · Cited by 385
Sullivan, S. G., Tchetgen Tchetgen, E. J., & Cowling, B. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww064 · Cited by 319
Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season
Jackson, M. L., Chung, J. R., Jackson, L. A., Phillips, C. H., Benoit, J., Monto, A. S., Martin, E. T., Belongia, E. A., McLean, H. Q., Gaglani, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700153 · Cited by 283
De Serres, G., Skowronski, D. M., Wu, X. W., & Ambrose, C. S. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.37.20585 · Cited by 245
Crowe, E., Pandeya, N., Brotherton, J. M. L., Dobson, A. J., Kisely, S., Lambert, S. B., & Whiteman, D. C. (2014) · BMJ · doi:10.1136/bmj.g1458 · Cited by 218
Palacios, R., Batista, A. P., Albuquerque, C. S. N., Patiño, E. G., Santos, J. D. P., Tilli Reis Pessoa Conde, M., Piorelli, R. D. O., Pereira Júnior, L. C., Raboni, S. M., Ramos, F., et al. (2021) · doi:10.2139/ssrn.3822780 · Cited by 198
Hitchings, M. D. T., Ranzani, O. T., Torres, M. S. S., de Oliveira, S. B., Almiron, M., Said, R., Borg, R., Schulz, W. L., de Oliveira, R. D., da Silva, P. V., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100025 · Cited by 197
Self-citationVictora, C. G., Castro, M. C., Gurzenda, S., de Medeiros, A. C., de França, G. V. A., & Barros, A. J. D. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101036 · Cited by 154
Bueno, S. M., Abarca, K., V, González, P. A., Gálvez, N. M. S., Soto, J. A., Duarte, L. F., Schultz, B. M., Pacheco, G. A., González, L. A., Vázquez, Y., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab823 · Cited by 148
Patel, M. K., Bergeri, I., Bresee, J., Cowling, B. J., Crowcroft, N. S., Fahmy, K., Hirve, S. S., Kang, G., Katz, M. A., Lanata, C. F., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.099 · Cited by 146
Britton, A., Jacobs Slifka, K. M., Edens, C., Nanduri, S. A., Bart, S. M., Shang, N., Harizaj, A., Armstrong, J., Xu, K., Ehrlich, H. Y., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7011e3 · Cited by 135
Freitas, A. R. R., Beckedorff, O. A., Cavalcanti, L. P. D. G., Siqueira, A. M., de Castro, D. B., da Costa, C. F., Lemos, D. R. Q., & de Barros, E. N. C. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100021 · Cited by 123
de Souza, W. M., Amorim, M. R., Sesti‐Costa, R., Coimbra, L. D., Brunetti, N. S., de Toledo-Teixeira, D. A., de Souza, G. F., Muraro, S. P., Parise, P. L., Barbosa, P. P., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00129-4 · Cited by 119
Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines
Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103
Moustsen-Helms, I. R., Emborg, H.-D., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K., Møller, K. L., Berthelsen, A.-S. N., & Valentiner-Branth, P. (2021) · doi:10.1101/2021.03.08.21252200 · Cited by 79
COVID-19 hospital admissions: Brazil's first and second waves compared
Bastos, L. D. S. L., Ranzani, O., Souza, T. M. L., Hamacher, S., & Bozza, F. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00287-3 · Cited by 77
Self-citationAssociations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbiditiesPreprint
Yelin, I., Katz, R., Herzel, E., Berman-Zilberstein, T., Ben‐Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R. (2021) · medRxiv · doi:10.1101/2021.03.16.21253686 · Cited by 76
Andrejko, K. L., Pry, J. M., Myers, J. F., Jewell, N. P., Openshaw, J. J., Watt, J., Jain, S., Lewnard, J. A., California COVID-19 Case-Control Study Team, Samani, H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab640 · Cited by 67
Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design
Schwartz, L. M., Halloran, M. E., Rowhani-Rahbar, A., Neuzil, K., & Victor, J. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.10.077 · Cited by 53
Prevention of COVID-19 by mRNA-based vaccines within the general population of CaliforniaPreprint
Andrejko, K. L., Pry, J. M., Myers, J. F., Jewell, N. P., Openshaw, J. J., Watt, J., Jain, S., & Lewnard, J. A. (2021) · medRxiv · doi:10.1101/2021.04.08.21255135 · Cited by 43
Case-control vaccine effectiveness studies: Data collection, analysis and reporting results
Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.035 · Cited by 38
Lamarca, A. P., de Almeida, L. G. P., Francisco, R. D. S., Agnez‐Lima, L. F., Scortecci, K. C., Perez, V. P., Brustolini, O. J. B., Sousa, E. S. S., Secco, D., Santos, Â., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009835 · Cited by 35
Skowronski, D., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D., Sbihi, H., Adam, S. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab616 · Cited by 32
Hitchings, M., Lewnard, J., Dean, N., Ko, A. I., Ranzani, O., Andrews, J. R., & Cummings, D. A. T. (2021) · medRxiv · doi:10.1097/ede.0000000000001484 · Cited by 31
Self-citationBaum, U., Poukka, E., Palmu, A., Salo, H., Lehtonen, T., & Leino, T. (2021) · medRxiv · doi:10.1371/journal.pone.0258704 · Cited by 21
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Zheng, C., Shao, W., Chen, X., Zhang, B., Wang, G., & Zhang, W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.009 · Cited by 693
Costa Clemens, S. A., Weckx, L., Clemens, R., Almeida Mendes, A. V., Ramos Souza, A., Silveira, M. B. V., da Guarda, S. N. F., de Nobrega, M. M., de Moraes Pinto, M. I., Gonzalez, I. G. S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00094-0 · Cited by 435
Metadata
- Authors
- Ranzani, O. T., Hitchings, M. D. T., Dorion, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W., Almiron, M., Said, R., de Oliveira, R. D., Vieira da Silva, P., de Araújo, W. N., Gorinchteyn, J. C., Andrews, J. R., Cummings, D. A. T., Ko, A. I., & Croda, J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-08-20
- Volume
- 374
- Pages
- n2015
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3195586705
- Cited by
- 348
- References
- 44
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.